SAN DIEGO–Illumina, Inc. (NASDAQ:ILMN) today announced that researchers at Baylor College of Medicine’s Medical Genetics Laboratories will use Illumina’s Infinium® High-Density (HD) DNA Analysis products to study genomic imprinting and its role in developmental diseases such as Prader-Willi syndrome (PWS), Angelman syndrome (AS), and other disorders caused by uniparental disomy. Baylor College of Medicine is committed to improving human health by providing the most current technologies for the medical genetics community. Illumina is showcasing the latest Information on its High-Density DNA Analysis products for cytogenetic research at the American College of Medical Genetics (ACMG) meeting this week in Tampa, Florida.

Arthur Beaudet, M.D., Professor and Chair of the Department of Molecular and Human Genetics at Baylor College of Medicine studies the role of epigenetic and de novo mutations in human disease. “We evaluated a variety of whole-genome arrays before opting to work with Illumina’s DNA Analysis products. Results from early tests show that we can quickly generate high-quality data using Illumina’s SNP arrays, providing us with the information required to more rapidly and accurately identify causative aberrations in the genome.”

Using Illumina’s Infinium DNA Analysis products, scientists at Baylor College of Medicine will have access to high-resolution scans of entire genomes for chromosomal abnormalities found in genes and disease pathways linked to common developmental diseases and syndromes. Different than FISH technologies, array-comparative genomic hybridization (CGH), or other karyotyping solutions, Illumina’s DNA Analysis products offer quick and cost effective screening for single-nucleotide polymorphisms (SNPs) associated with diseases, structural variation, and copy-neutral loss of heterozygosity (LOH) events such as uniparental disomy (UPD), which are undetectable on current array-CGH products.

“It’s exciting to see prominent facilities across the country, like the Baylor College of Medicine, adopting Illumina’s DNA Analysis products for molecular cytogenetic services,” said Tristan Orpin, Senior Vice President of Commercial Operations at Illumina. “Our products are designed to work in any laboratory and include the content necessary for detecting various congenital disorders across the whole genome. Combined with an automated workflow, researchers have access to a fast, high quality solution not available with other technologies.”

About Baylor College of Medicine

Baylor College of Medicine in Houston, Texas is the only private medical school in the Greater Southwest, and is recognized as a premiere academic health science center, known for excellence in education, research, and patient care. Located in the Texas Medical Center, Baylor College of Medicine has affiliations with eight teaching hospitals, each known for medical excellence.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, DNA analysis, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to integrate effectively our recent acquisition of Solexa, Inc., (ii) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and DNA analysis products and applications for our technology platforms, (iii) to manufacture robust microarrays and Oligator® oligonucleotides, (iv) to integrate and scale our VeraCode technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.